172 related articles for article (PubMed ID: 24586533)
21. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
[TBL] [Abstract][Full Text] [Related]
22. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells.
Tsui KH; Lin YF; Chen YH; Chang PL; Juang HH
J Androl; 2011; 32(4):383-93. PubMed ID: 21051589
[TBL] [Abstract][Full Text] [Related]
24. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
[TBL] [Abstract][Full Text] [Related]
25. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression.
Hsieh TC; Wu JM
Prostate; 1997 Oct; 33(2):97-104. PubMed ID: 9316650
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells.
Tsui KH; Chang PL; Lin HT; Juang HH
J Urol; 2004 Nov; 172(5 Pt 1):2035-9. PubMed ID: 15540784
[TBL] [Abstract][Full Text] [Related]
27. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
Liu Y; Liu Y; Yuan B; Yin L; Peng Y; Yu X; Zhou W; Gong Z; Liu J; He L; Li X
Oncotarget; 2017 Mar; 8(10):17027-17037. PubMed ID: 28199985
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
29. Regulation of Btg2(/TIS21/PC3) expression via reactive oxygen species-protein kinase C-ΝFκΒ pathway under stress conditions.
Imran M; Lim IK
Cell Signal; 2013 Dec; 25(12):2400-12. PubMed ID: 23876794
[TBL] [Abstract][Full Text] [Related]
30. Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element.
Kregel S; Bagamasbad P; He S; LaPensee E; Raji Y; Brogley M; Chinnaiyan A; Cieslik M; Robins DM
Nucleic Acids Res; 2020 May; 48(9):4741-4755. PubMed ID: 32198885
[TBL] [Abstract][Full Text] [Related]
31. Estradiol Prevents High Glucose-Induced β-cell Apoptosis by Decreased BTG2 Expression.
Kooptiwut S; Kaewin S; Semprasert N; Sujjitjoon J; Junking M; Suksri K; Yenchitsomanus PT
Sci Rep; 2018 Aug; 8(1):12256. PubMed ID: 30115961
[TBL] [Abstract][Full Text] [Related]
32. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.
Coppola V; Musumeci M; Patrizii M; Cannistraci A; Addario A; Maugeri-Saccà M; Biffoni M; Francescangeli F; Cordenonsi M; Piccolo S; Memeo L; Pagliuca A; Muto G; Zeuner A; De Maria R; Bonci D
Oncogene; 2013 Apr; 32(14):1843-53. PubMed ID: 22614007
[TBL] [Abstract][Full Text] [Related]
33. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
[TBL] [Abstract][Full Text] [Related]
34. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
35. Emodin induces apoptosis in human prostate cancer cell LNCaP.
Yu CX; Zhang XQ; Kang LD; Zhang PJ; Chen WW; Liu WW; Liu QW; Zhang JY
Asian J Androl; 2008 Jul; 10(4):625-34. PubMed ID: 18478162
[TBL] [Abstract][Full Text] [Related]
36. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
[TBL] [Abstract][Full Text] [Related]
37. Differential CARM1 expression in prostate and colorectal cancers.
Kim YR; Lee BK; Park RY; Nguyen NT; Bae JA; Kwon DD; Jung C
BMC Cancer; 2010 May; 10():197. PubMed ID: 20462455
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells.
Lee JC; Chung LC; Chen YJ; Feng TH; Chen WT; Juang HH
Cancer Lett; 2015 May; 360(2):310-8. PubMed ID: 25721086
[TBL] [Abstract][Full Text] [Related]
39. Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Zhang J; Li Q; Zhang S; Xu Q; Wang T
Exp Cell Res; 2016 Nov; 349(1):77-84. PubMed ID: 27743893
[TBL] [Abstract][Full Text] [Related]
40. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
